Top

International Urogynecology Journal

Published in:

01-01-2021 | Overactive Bladder | Original Article

Comparison of the effects of trospium and solifenacin on intraocular pressure and tear secretion in patients with overactive bladder

Authors: Ali Riza Turkoglu, Neslihan Parmak Yener, Muhammet Guzelsoy, Soner Coban, Hakan Demirci

Published in: International Urogynecology Journal | Issue 1/2021

Abstract

Introduction and hypothesis

Comparison of the effects of trospium and solifenacin used for the treatment of overactive bladder (OAB) on intraocular pressure (IOP) and tear secretion.

Methods

This study was planned as a prospective study and was conducted at a single center between October 2014 and April 2016. OAB patients were included in the study following an ophthalmic examination, IOP measurement with an applanation tonometer, and tear secretion measurement with the Schirmer I test in the ophthalmology outpatient department. The patients were started with trospium 30 mg oral bid or solifenacin 5 mg oral qd. They were then followed up at the 4th and 12th weeks.

Results

A total of 225 OAB patients with a mean age of 47.80 (18–75) years were evaluated. The mean age was 47.41 ± 12.65 years in the trospium group (n = 104) and 48.14 ± 11.82 years in the solifenacin group (n = 121) with no statistically significant difference. When the two medications were compared, no statistically significant difference was observed at the 4th and 12th weeks in terms of IOP (p = 0.988, p = 0.822) and dry eye (p = 0.764, p = 0.581).

Conclusions

No statistically significant difference was observed between trospium and solifenacin in terms of their effects on IOP and tear secretion in OAB patients. We therefore concluded that the effects of trospium and solifenacin on IOP and tear secretion changes were similar in OAB patients without comorbidities.

Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the international continence society. Neurourol Urodyn. 2002;21(2):167–78.

Milsom I, Abrams P, Cardozo L, Robert RG, Thüroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001;87(9):760–6.CrossRef

Andersson KE. Antimuscarinics for the treatment of overactive bladder. Lancet Neurol. 2004;3(1):46–53.CrossRef

Hartmann KE, McPheeters ML, Biller DH, Ward RM, McKoy JN, Jerome RN, et al. Treatment of overactive bladder in women. Evid Rep Technol Assess. 2009;187:1–120.

Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54:543–62.CrossRef

Quigley HA, Friedman DS, Congdon NG. Possible mechanisms of primary angle closure and malignant glaucoma. J Glaucoma. 2003;12(2):167–80.CrossRef

Clegg JP, Guest JF, Lehman A, Smith AF. The annual cost of dry eye syndrome in France, Germany, Italy, Spain, Sweden and the United Kingdom among patients managed by ophthalmologists. Ophthalmic Epidemiol. 2006;13:263–74.CrossRef

Janine AS, Julie A, Carolyn B, Ca B, Kelly N, Debra S, et al. The epidemiology of dry eye disease: report of the epidemiology subcommittee of the international dry eye workshop. Ocul Surf. 2007;5:93–107.CrossRef

Homma Y, Kakizaki H, Gotoh M. Epidemiologic survey on urination. J Jpn Neurogenic Bladder Soc. 2003;14:266–77.

10.

Iwase A. The prevalence of glaucoma in Japan. Ganka. 2003;45:733–9.

11.

Olcucu MT, Teke K, Yildirim K, Togac M, Işık B, Yilmaz YC. Comparision effects of Solifenacin, Darifenacin, Propiverine on ocular parameters in eyes: a prospective study. Int Braz J Urol. 2020;46(2):185–93.CrossRef

12.

Faul F, Erdfelder E, Lang AG, Buchner A. G*power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39(2):175–91.CrossRef

13.

Sekeroglu MA, Hekimoglu E, Tasci Y, Dolen I, Arslan U. Ocular surface changes following oral anticholinergic use for overactive bladder. Cutan Ocul Toxicol. 2016;35(3):218–21.CrossRef

14.

Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int. 2007;100(5):987–1006.CrossRef

15.

Andersson K, Wein A. Pharmacologic Management of Storage and Emptying Failure. In: Wein Alan J, editor. Campbell-Walsh urology. Philadelphia: Saunders Elsevier; 2007. p. 2091–123.

16.

Tripathi RC, Tripathi BJ, Haggerty C. Drug-induced glaucomas: mechanism and management. Drug Saf. 2003;26(11):749–67.CrossRef

17.

Turkoglu AR, Parmak Yener N, Coban S, Guzelsoy M, Emul A, Demirbas M, et al. Effect of trospium chloride therapy on intraocular pressure and tear secretion in overactive bladder patients. Cutan Ocul Toxicol. 2017;4:1–5.

18.

Turkoglu AR, Yener NP, Coban S, Guzelsoy M, Demirbas M, Demirci H. Changes in intraocular pressure and tear secretion in patients given 5 mg solifenacin for the treatment of overactive bladder. Int Urogynecol J. 2017;28(5):777–81.CrossRef

19.

Jain D, Dhua A, Ravisankar V, Chellam L, Joshi MJ. Acute angle closure glaucoma after hypospadias surgery: a vision-threatening complication of oxybutynine. J Indian Assoc Pediatr Surg. 2015;20(3):161–2.CrossRef

20.

Sun X, Dai Y, Chen Y, Yu DY, Cringle SJ, Chen J et al. (2016) Primary angle closure glaucoma: What we know and what we don’t know, Progress in Retinal and Eye Research https://doi.org/10.1016/j.preteyeres.2016.12.003

21.

Wright C, Tawfik MA, Waisbourd M, Katz LJ. Primary angle-closure glaucoma: an update. Acta Ophthalmol. 2016;94(3):217–25.CrossRef

22.

Thomas R, George R, Parikh R, Muliyil J, Jacob A. Five year risk of progression of primary angle closure suspects to primary angle closure: a population based study. Br J Ophthalmol. 2003;87:450–4.CrossRef

23.

Thomas R, Parikh R, Muliyil J, Kumar RS. Five-year risk of progression of primary angle closure to primary angle closure glaucoma: a population-based study. Acta Ophthalmol Scand. 2003;81:480–5.CrossRef

24.

Yip JL, Foster PJ, Gilber CE, Uranchimeg D, Bassanhuu J, Lee PS. Incidence of occludable angles in a high-risk mongolian population. Br J Ophthalmol. 2008;92:30–3.CrossRef

25.

Bacman S, PerezLeiros C, Sterin-Borda L, Hubscher O, Arana R, Borda E. Auto antibodies against lacrimal gland M3 muscarinic acetylcholine receptor in patients with primary Sjögren’s syndrome. Invest Ophtalmol Vis Sci. 1998;39(1):151–6.

26.

American Academy of Ophthalmology. External disease and cornea. Basic and clinical science course section 8. San Francisco. 2005;4:53–61 No authors listed.

27.

Altan-Yaycioglu R, Yaycioglu O, Aydin Akova Y, Guyel S, Ozkardes H. Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial. Br J Clin Pharmacol. 2005;59(5):588–92.CrossRef

28.

Tunay ZO, Ozdemir O, Acar DE, Cavkaytar S, Ersoy E. Dry eye findings worsen with anticholinergic therapy in patients with urge incontinence. Int Urogynecol J. 2016;27(6):919–22.CrossRef

Title: Comparison of the effects of trospium and solifenacin on intraocular pressure and tear secretion in patients with overactive bladder
Authors: Ali Riza Turkoglu
Neslihan Parmak Yener
Muhammet Guzelsoy
Soner Coban
Hakan Demirci
Publication date: 01-01-2021
Publisher: Springer International Publishing
Keywords: Overactive Bladder
Trospium
Solifenacin
Published in: International Urogynecology Journal / Issue 1/2021
Print ISSN: 0937-3462
Electronic ISSN: 1433-3023
DOI: https://doi.org/10.1007/s00192-020-04473-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Comparison of the effects of trospium and solifenacin on intraocular pressure and tear secretion in patients with overactive bladder

Abstract

Introduction and hypothesis

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction and hypothesis

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Correction to: Urethral closure occurs by recoiling, pressure transmission, and a guarding reflex

Surgical management of stress urinary incontinence following traumatic pelvic injury

Is the fixation of single incision TVT-S tape as good as that of transobturator tape? An ultrasound study of randomized trial results

OnabotulinumtoxinA is a well tolerated and effective treatment for refractory overactive bladder in real-world practice

Primary identification and reparation of the “buttonhole” tears is necessary

Correction to: Does concurrent posterior repair for an asymptomatic rectocele reduce the risk of surgical failure in patients undergoing sacrocolpopexy?